Advertisement

DGNeurologie

pp 1–20 | Cite as

S1-Leitlinie: Diagnostik bei Polyneuropathien

Leitlinie der Deutschen Gesellschaft für Neurologie
  • D. HeußEmail author
Leitlinie
  • 8 Downloads

Was gibt es Neues?

  • In einer Untergruppe von Patienten mit einer chronisch inflammatorischen demyelinisierenden Polyneuropathie (CIDP) wurden spezifische Antikörper (NF 155, NF 186 [NF: Neurofaszin] und Contactin 1) gegen Moleküle des nodalen/paranodalen Komplexes entdeckt, die die Nervenerregungsleitung entlang myelinisierter Fasern blockieren. Patienten mit immunvermittelten Neuropathien und diesen Antikörpern haben besondere Phänotypen und sprechen oft schlechter auf Standardtherapien der CIDP, aber sehr gut auf Rituximab an [1, 2].

  • Neue Medikamente in der Krebstherapie, die sog. Immuncheckpointinhibitoren (wie z. B. Ipilimumab, Nivolumab und Pembrolizumab), können selten mit schweren zentralen und peripheren neurologischen Nebenwirkungen einhergehen, darunter den akuten inflammatorischen demyelinisierenden oder axonalen Polyneuropathien (AIDP [akute entzündliche demyelinisierende Polyradikuloneuropathie]/ASMAN [akute sensomotorische axonale Neuropathie]/AMN [Adrenomyeloneuropathie])...

S1 guideline: diagnosis of polyneuropathies

Guideline of the German Neurological Society

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

Siehe Interessenkonflikterklärung auf www.dgn.org/leitlinien.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Doppler K, Sommer C (2017) Neue Entität der Paranodopathien: eine Ziel-struktur mit therapeutischen Konsequenzen. Aktuelle Neurol 44:194–199CrossRefGoogle Scholar
  2. 2.
    Querol L, Devaux J, Rojas-Garcia R, Illa I (2017) Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol 13(9):533–547PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Eggermann K, Gess B, Hausler M, Weis J, Hahn A, Kurth I (2018) Hereditary neuropathies. Dtsch Arztebl Int 115(6):91–97PubMedPubMedCentralGoogle Scholar
  4. 4.
    Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Dyck P, Thomas P, Griffin J, Low P, Poduslo J (1993) Peripheral neuropathy, 3. Aufl. W.B. Saunders Company, PhiladelphiaGoogle Scholar
  7. 7.
    Mendell J, Kissel J, Cornblath D (2001) Diagnosis and management of peripheral nerve disorders. Oxford University Press, OxfordGoogle Scholar
  8. 8.
    Neundörfer B, Heuß D (2006) Polyneuropathien, 1. Aufl. Thieme, Stuttgart, S 129Google Scholar
  9. 9.
    Pestronk A Neuromuscular Disorders. http://neuromuscular.wustl.edu/
  10. 10.
    Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barre syndrome. Lancet 388(10045):717–727PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Albert SM, Wohl MA, Rechtman AM (1958) Serum neuropathy following routine use of tetanus antitoxin; report of five cases. Am Pract Dig Treat 9(8):1249–1252PubMedPubMedCentralGoogle Scholar
  12. 12.
    Baust W, Meyer D, Wachsmuth W (1979) Peripheral neuropathy after administration of tetanus toxoid. J Neurol 222(2):131–133PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Blumstein GI, Kreithen H (1966) Peripheral neuropathy following tetanus toxoid administration. JAMA 198(9):1030–1031PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Pollard JD, Selby G (1978) Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 37(1–2):113–125PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Reinstein L, Pargament JM, Goodman JS (1982) Peripheral neuropathy after multiple tetanus toxoid injections. Arch Phys Med Rehabil 63(7):332–334PubMedPubMedCentralGoogle Scholar
  16. 16.
    Prasad PL, Rai PL (2018) Prospective study of diphtheria for neurological complications. J Pediatr Neurosci 13(3):313–316PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Rattananan W, Thaisetthawatkul P, Dyck PJ (2014) Postsurgical inflammatory neuropathy: a report of five cases. J Neurol Sci 337(1–2):137–140PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Unfallversicherung DDG (2018) BK 1317 – Polyneuropathie oder Enzephalopathie durch organische Lösungsmittel oder deren Gemische (BK-Report 1/2018). https://www.dguv.de/ifa/publikationen/reports-download/reports-2018/bk-report-1-2018/index.jsp
  19. 19.
    de Langen JJ, van Puijenbroek EP (2006) HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. Neth J Med 64(9):334–338PubMedPubMedCentralGoogle Scholar
  20. 20.
    Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Bressler AM, Zimmer SM, Gilmore JL, Somani J (2004) Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4(8):528–531PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS (2006) Linezolid-associated toxic optic neuropathy. Neurology 66(4):595–598PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G (2017) Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 45:14–17PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Reinhardt F, Wetzel T, Vetten S, Radespiel-Troger M, Hilz MJ, Heuss D et al (2000) Peripheral neuropathy in chronic venous insufficiency. Muscle Nerve 23(6):883–887PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Tankisi H, Pugdahl K, Johnsen B, Fuglsang-Frederiksen A (2007) Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies. Clin Neurophysiol 118(11):2383–2392PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Buchner H, Schönlau L, Ferbert A (2018) Neurographie des N. Suralis. Klin Neurophysiol 49:188–207CrossRefGoogle Scholar
  27. 27.
    Stöhr M (1998) Atlas der klinischen Elektromyographie und Neurographie, 4. Aufl. Kohlhammer, StuttgartGoogle Scholar
  28. 28.
    Bromberg MB, Franssen H (2015) Practical rules for electrodiagnosis in suspected multifocal motor neuropathy. J Clin Neuromuscul Dis 16(3):141–152PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Heuß D, Müller-Felber W, Schulte-Mattler W, Dengler R, Toyka K, Sommer C (2002) Diagnostik und Therapie der multifokalen motorischen Neuropathie (MMN). Bundeseinheitliche Konsensuspapiere der Muskelzentren im Auftrag der Deutschen Gesellschaft für Muskelkranke e. V. (DGM). Nervenheilkunde (21):100–107Google Scholar
  30. 30.
    Joint Task Force of the E, the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst 15(4):295–301CrossRefGoogle Scholar
  31. 31.
    Akaza M, Kanouchi T, Inaba A, Numasawa Y, Irioka T, Mizusawa H et al (2011) Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve 43(2):274–282PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Jaspert A, Claus D, Grehl H, Kerling F, Neundorfer B (1995) Value of proximal conduction block study in diagnosis of inflammatory neuropathies. Nervenarzt 66(6):445–454PubMedPubMedCentralGoogle Scholar
  33. 33.
    Atherton DD, Facer P, Roberts KM, Misra VP, Chizh BA, Bountra C et al (2007) Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol 7:21PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Obermann M, Katsarava Z, Esser S, Sommer C, He L, Selter L et al (2008) Correlation of epidermal nerve fiber density with pain-related evoked potentials in HIV neuropathy. Pain 138(1):79–86PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Casanova-Molla J, Grau-Junyent JM, Morales M, Valls-Sole J (2011) On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain 152(2):410–418PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Rage M, Van Acker N, Knaapen MW, Timmers M, Streffer J, Hermans MP et al (2011) Asymptomatic small fiber neuropathy in diabetes mellitus: investigations with intraepidermal nerve fiber density, quantitative sensory testing and laser-evoked potentials. J Neurol 258:1852PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Tavakoli M, Marshall A, Pitceathly R, Fadavi H, Gow D, Roberts ME et al (2010) Corneal confocal microscopy: a novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol 223(1):245–250PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Wilbourn A (2000) Multiple mononeuropathies and polyneuropathies. In: Levin K, Luders HO (Hrsg) Comprehensive clinical neurophysiology. W.B. Saunders Company, Philadelphia, London, New York, St. Louis, Sydney, Toronto, S 215–233Google Scholar
  39. 39.
    Hamel J, Logigian EL (2018) Acute nutritional axonal neuropathy. Muscle Nerve 57(1):33–39PubMedCrossRefGoogle Scholar
  40. 40.
    Pestronk A Neuromuscular. Neuromuscular Disease Center Washington University, St. Louis ( https://neuromuscular.wustl.edu/autonomic.html .)
  41. 41.
    van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP et al (2014) Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 82(6):491–497PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Munoz-Jordan JL et al (2018) Clinical features of Guillain-barre syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol 75(9):1089–1097PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Goodfellow JA, Willison HJ (2018) Gangliosides and autoimmune peripheral nerve diseases. Prog Mol Biol Transl Sci 156:355–382PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Klehmet J, Marschenz S, Ruprecht K, Wunderlich B, Buttner T, Hiemann R et al (2018) Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab Med 56(6):919–926PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Fehmi J, Scherer SS, Willison HJ, Rinaldi S (2018) Nodes, paranodes and neuropathies. J Neurol Neurosurg Psychiatry 89(1):61–71PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Uncini A, Vallat JM (2018) Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. J Neurol Neurosurg Psychiatry 89(6):627–635PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Binks S, Varley J, Lee W, Makuch M, Elliott K, Gelfand JM et al (2018) Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain 141(8):2263–2271PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Sghirlanzoni A, Pareyson D, Lauria G (2005) Sensory neuron diseases. Lancet Neurol 4(6):349–361PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Antoine JC, Boutahar N, Lassabliere F, Reynaud E, Ferraud K, Rogemond V et al (2015) Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry 86(12):1347–1355PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Gibbons CH, Freeman R (2015) Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 138(Pt 1):43–52PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Mohseni S (2001) Hypoglycemic neuropathy. Acta Neuropathol 102(5):413–421PubMedPubMedCentralGoogle Scholar
  52. 52.
    Ozaki K, Sano T, Tsuji N, Matsuura T, Narama I (2010) Insulin-induced hypoglycemic peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats. Comp Med 60(4):282–287PubMedPubMedCentralGoogle Scholar
  53. 53.
    Kumar N (2014) Neurologic aspects of cobalamin (B12) deficiency. Handb Clin Neurol 120:915–926PubMedCrossRefGoogle Scholar
  54. 54.
    Santos-Garcia D, de la Fuente-Fernandez R, Valldeoriola F, Palasi A, Carrillo F, Grande M et al (2012) Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert. J Neurol 259(8):1668–1672PubMedCrossRefGoogle Scholar
  55. 55.
    Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Muller-Quernheim J (2008) Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 177(3):330–336PubMedCrossRefGoogle Scholar
  56. 56.
    Ufer F, Friese M (2015) Neurosarkoidose. Aktuelle Neurol 42:218–227CrossRefGoogle Scholar
  57. 57.
    Nobile-Orazio E, Bianco M, Nozza A (2017) Advances in the treatment of paraproteinemic neuropathy. Curr Treat Options Neurol 19(12):43PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Theaudin M, Adam C et al (2018) Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91(2):e143–e152PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H et al (2011) Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8(1):48–58PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    van Sonderen A, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87(5):521–528PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M et al (2016) Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86(9):800–807PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Doppler K, Appeltshauser L, Wilhelmi K, Villmann C, Dib-Hajj SD, Waxman SG et al (2015) Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 86(7):720–728PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N et al (2017) Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. J Neuroimmunol 309:41–46PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AH et al (2015) Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138(Pt 6):1484–1491PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Heuß D (2006) Untersuchungen des Liquor cerebrospinalis. In: Neundörfer B, Heuß D (Hrsg) Polyneuropathien. Referenzreihe Neurologie RRN. Thieme, Stuttgart, S 32–35 (Tafel IX)Google Scholar
  67. 67.
    Bourque PR, Breiner A, Moher D, Brooks J, Hegen H, Deisenhammer F et al (2019) Adult CSF total protein: Higher upper reference limits should be considered worldwide. A web-based survey. J Neurol Sci 396:48–51PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Allen JA, Lewis RA (2015) CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85(6):498–504PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Asbrink E (1997) Peripheral neuropathy in acrodermatitis chronica atrophicans—a late Borrelia manifestation. Acta Neurol Scand 95(6):338–345PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
  71. 71.
    Antoniadi T, Buxton C, Dennis G, Forrester N, Smith D, Lunt P et al (2015) Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield with unexpected phenotype-genotype variability. BMC Med Genet 16:84PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Baets J, Deconinck T, De Vriendt E, Zimon M, Yperzeele L, Van Hoorenbeeck K et al (2011) Genetic spectrum of hereditary neuropathies with onset in the first year of life. Brain 134(Pt 9):2664–2676PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J et al (2017) Genetic heterogeneity of motor neuropathies. Neurology 88(13):1226–1234PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Hoeijmakers JG, Faber CG, Lauria G, Merkies IS, Waxman SG (2012) Small-fibre neuropathies—advances in diagnosis, pathophysiology and management. Nat Rev Neurol 8(7):369–379PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Kurth I (2015) Sensory and autonomic neuropathies and pain-related channelopathies. Schmerz 29(4):445–457PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Rossor AM, Polke JM, Houlden H, Reilly MM (2013) Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 9(10):562–571PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Tazir M, Bellatache M, Nouioua S, Vallat JM (2013) Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst 18(2):113–129PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA et al (2009) Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Pm R 1(1):5–13PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Neundörfer B, Rautenstrauss B (2006) Hereditäre Polyneuropathien. In: Neundörfer B, Heuß D (Hrsg) Polyneuropathien. Thieme, Stuttgart, S 100–109Google Scholar
  80. 80.
    Pestronk A Neuromuscular disorders—hereditary neuropathies. http://neuromuscular.wustl.edu/time/hmsn.html
  81. 81.
    Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME (2011) Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69(1):22–33PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Hund E (2014) Hereditary transthyretin amyloidosis. Nervenarzt 85(10):1291–1297PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML et al (2016) „Red flag“ symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5–9PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Goedee HS, Brekelmans GJ, van Asseldonk JT, Beekman R, Mess WH, Visser LH (2013) High resolution sonography in the evaluation of the peripheral nervous system in polyneuropathy—a review of the literature. Eur J Neurol 20(10):1342–1351PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Üçeyler N (2016) Ultraschall in der Diagnostik von Polyneuropathien. Aktuelle Neurol 43:548–556CrossRefGoogle Scholar
  86. 86.
    Goedee HS, van der Pol WL, van Asseldonk JH, Franssen H, Notermans NC, Vrancken AJ et al (2017) Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 88(2):143–151PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Bernabeu A, Lopez-Celada S, Alfaro A, Mas JJ, Sanchez-Gonzalez J (2016) Is diffusion tensor imaging useful in the assessment of the sciatic nerve and its pathologies? Our clinical experience. Br J Radiol 89(1066):20150728PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Lichtenstein T, Sprenger A, Weiss K, Slebocki K, Cervantes B, Karampinos D et al (2018) MRI biomarkers of proximal nerve injury in CIDP. Ann Clin Transl Neurol 5(1):19–28PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Sinclair CD, Miranda MA, Cowley P, Morrow JM, Davagnanam I, Mehta H et al (2011) MRI shows increased sciatic nerve cross sectional area in inherited and inflammatory neuropathies. J Neurol Neurosurg Psychiatry 82(11):1283–1286PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Kronlage M, Pitarokoili K, Schwarz D, Godel T, Heiland S, Yoon MS et al (2017) Diffusion tensor imaging in chronic inflammatory demyelinating polyneuropathy: diagnostic accuracy and correlation with electrophysiology. Invest Radiol 52(11):701–707PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Goedee HS, Jongbloed BA, van Asseldonk JH, Hendrikse J, Vrancken A, Franssen H et al (2017) A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. Eur J Neurol 24(10):1307–1313PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Antoine JC, Camdessanche JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30(5):513–520PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Camdessanche JP, Jousserand G, Franques J, Pouget J, Delmont E, Creange A et al (2012) A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: a French collaborative study. J Peripher Nerv Syst 17(3):331–340PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F et al (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 18(1):19–19e3PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Dispenzieri A (2017) POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol 92(8):814–829PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Adams D, Cauquil C, Labeyrie C (2017) Familial amyloid polyneuropathy. Curr Opin Neurol 30(5):481–489PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Adams D, Lozeron P, Lacroix C (2012) Amyloid neuropathies. Curr Opin Neurol 25(5):564–572PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D et al (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15(3):176–184PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Collins MP, Hadden RD (2017) The nonsystemic vasculitic neuropathies. Nat Rev Neurol 13(5):302–316PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Heuß D (2006) Morphologische Untersuchungen bei Polyneuropathien – Nerven- und Muskelbiopsie. In: Neundörfer B, Heuß D (Hrsg) Polyneuropathien. Referenzreihe Neurologie RRN. Thieme, Stuttgart, S 19–22 (Tafel I–VII.)Google Scholar
  101. 101.
    Sommer CL, Brandner S, Dyck PJ, Harati Y, LaCroix C, Lammens M et al (2010) Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst 15(3):164–175PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS et al (2000) Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 55(5):636–643PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Leuschner T, Probst-Cousin S, Kayser C, Neundörfer B, Heuß D (2001) Reliabilität morphologischer Methoden in der Diagnostik einer vaskulitischen Neuropathie. Nervenheilkunde 40:20Google Scholar
  104. 104.
    Vital C, Vital A, Canron MH, Jaffre A, Viallard JF, Ragnaud JM et al (2006) Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 11(1):20–29PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Vrancken AF, Gathier CS, Cats EA, Notermans NC, Collins MP (2011) The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy. Eur J Neurol 18(1):49–58PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Üçeyler N, Devigili G, Toyka KV, Sommer C (2010) Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy. Acta Neuropathol 120(1):109–116PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Verschueren A (2007) Immune-mediated neuropathies: indications and value of nerve biopsy. Rev Neurol 163(Spec No 1):3S58–3S60PubMedPubMedCentralGoogle Scholar
  108. 108.
    Allen JA, Gorson KC, Gelinas D (2018) Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. Brain Behav 8(3):e932PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Sommer C (2018) Fortschr Neurol Psychiatr 86:509–518PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS (2017) The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 16(11):934–944PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Levine TD (2018) Small fiber neuropathy: disease classification beyond pain and burning. J Cent Nerv Syst Dis 10:1179573518771703PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Blackmore D, Siddiqi ZA (2017) Diagnostic criteria for small fiber neuropathy. J Clin Neuromuscul Dis 18(3):125–131PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Joint Task Force of the E, the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. J Peripher Nerv Syst 15(1):1–9CrossRefGoogle Scholar
  114. 114.
    Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806–812PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Echaniz-Laguna A, de Seze J, Chanson JB (2012) Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. J Neurol Neurosurg Psychiatry 83(7):699–705PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Karam C, Mauermann ML, Johnston PB, Lahoria R, Engelstad JK, Dyck PJ (2014) Immune-mediated neuropathies following stem cell transplantation. J Neurol Neurosurg Psychiatry 85(6):638–642PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Romero S, Montoro J, Guinot M, Almenar L, Andreu R, Balaguer A et al (2018) Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma 60:1–9Google Scholar
  118. 118.
    Julian T, Glascow N, Syeed R, Zis P (2018) Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol.  https://doi.org/10.3201/eid2202.141762 CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Mellion M, Gilchrist JM, de la Monte S (2011) Alcohol-related peripheral neuropathy: nutritional, toxic, or both? Muscle Nerve 43(3):309–316PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Mellion ML, Silbermann E, Gilchrist JM, Machan JT, Leggio L, de la Monte S (2014) Small-fiber degeneration in alcohol-related peripheral neuropathy. Alcohol Clin Exp Res 38(7):1965–1972PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Callaghan BC, Hur J, Feldman EL (2012) Diabetic neuropathy: one disease or two? Curr Opin Neurol 25(5):536–541PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Polydefkis M, Griffin JW, McArthur J (2003) New insights into diabetic polyneuropathy. JAMA 290(10):1371–1376PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Visser NA, Notermans NC, Linssen RS, van den Berg LH, Vrancken AF (2015) Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 84(3):259–264PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M (2016) Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol 263(10):1903–1910PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Finsterer J, Wanschitz J, Quasthoff S, Iglseder S, Loscher W, Grisold W (2017) Causally treatable, hereditary neuropathies in Fabry’s disease, transthyretin-related familial amyloidosis, and Pompe’s disease. Acta Neurol Scand 136(6):558–569PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Heuss D (2019) Therapie der Polyneuropathien. In: Therapie-Handbuch. Elsevier – Urban & Fischer ( http://www1.us.elsevierhealth.com/THB/chapter_P011.php )
  127. 127.
    Sommer C, Gold R, Heuss D et al.Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden, S2e-Leitlinie. In: Neurologie DGf, editor. Leitlinien für Diagnostik und Therapie in der Neurologie: AWMF online. Das Portal der wissenschaftlichen Medizin; 2018. Google Scholar

Copyright information

© DGN 2019

Authors and Affiliations

  1. 1.Neurologische KlinikUniversitätsklinikum ErlangenErlangenDeutschland

Personalised recommendations